114 related articles for article (PubMed ID: 18007566)
1. Commentary on the treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Carlat DJ
Psychopharmacol Bull; 2007; 40(3):29-31. PubMed ID: 18007566
[No Abstract] [Full Text] [Related]
2. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ
Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565
[TBL] [Abstract][Full Text] [Related]
3. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
Tobin M
Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
[No Abstract] [Full Text] [Related]
4. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
Bodkin JA; Amsterdam JD
Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
[TBL] [Abstract][Full Text] [Related]
5. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
[TBL] [Abstract][Full Text] [Related]
6. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
7. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
[TBL] [Abstract][Full Text] [Related]
8. A critical appraisal of the selegiline transdermal system for major depressive disorder.
Bied AM; Kim J; Schwartz TL
Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
[TBL] [Abstract][Full Text] [Related]
9. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD
J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
[TBL] [Abstract][Full Text] [Related]
11. Selegiline transdermal system in major depressive disorder: profile report.
Frampton JE; Plosker GL
CNS Drugs; 2007; 21(6):521-4. PubMed ID: 17521230
[No Abstract] [Full Text] [Related]
12. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
Robinson DS; Amsterdam JD
J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
[TBL] [Abstract][Full Text] [Related]
13. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L; Goldberg JF; Portland KB
J Affect Disord; 2013 Nov; 151(2):409-417. PubMed ID: 23890583
[TBL] [Abstract][Full Text] [Related]
14. Transdermal selegiline in patients receiving electroconvulsive therapy.
Horn PJ; Reti I; Jayaram G
Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
[TBL] [Abstract][Full Text] [Related]
15. Critical appraisal of selegiline transdermal system for major depressive disorder.
Cristancho MA; Thase ME
Expert Opin Drug Deliv; 2016; 13(5):659-65. PubMed ID: 26837935
[TBL] [Abstract][Full Text] [Related]
16. Selegiline transdermal system Somerset.
Mahmood I
Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
[TBL] [Abstract][Full Text] [Related]
17. Monoamine oxidase inhibitors: a new generation.
Robinson DS
Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
[TBL] [Abstract][Full Text] [Related]
18. Monoamine oxidase inhibitors revisited: what you should know.
Goldberg JF; Thase ME
J Clin Psychiatry; 2013 Feb; 74(2):189-91. PubMed ID: 23473352
[No Abstract] [Full Text] [Related]
19. Pharmacotherapy for late-life depression.
Alexopoulos GS
J Clin Psychiatry; 2011 Jan; 72(1):e04. PubMed ID: 21272511
[TBL] [Abstract][Full Text] [Related]
20. Selegiline transdermal system: a novel treatment option for major depressive disorder.
Nandagopal JJ; DelBello MP
Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
